belle labs · prefilled pen

re.triple-gthe last variable.

triple receptor agonist · glp-1 · gip · glucagon

three receptors. one molecule.
your metabolism responds to all of them simultaneously —
reducing intake, increasing output, reshaping composition.

this is not incremental. this is a different category.

€449
per penprefilled · pharmaceutical grade
request access →

available by request only

glp-1r gipr gcgr re.triple-g
what changes
the experience

not one signal.
three — working
at the same time.

most interventions address one lever at a time. re.triple-g activates three metabolic receptors simultaneously — reducing intake, accelerating output, and reshaping composition in a way no single-receptor approach can replicate.

01
appetite regulation
glp-1 receptor activation modulates satiety signals and gastric emptying — intake reduces without effort or restriction.
02
metabolic output
glucagon receptor activation increases energy expenditure and lipolysis — the body burns more, independently of activity level.
03
body composition
visceral fat responds. studies show significant reductions in fat mass alongside preserved lean tissue.
04
sustained availability
engineered with a lipophilic side chain for extended half-life. one pen. consistent systemic presence throughout the week.
3
receptors activated
glp-1r, gipr, and gcgr — simultaneously. no other class of molecule works this way.
39
amino acids
a precisely engineered 39-amino-acid sequence with lipid modification for extended systemic availability.
coa
full documentation
certificate of analysis and batch traceability available for every order upon request.
for those who want to understand the science
+

re.triple-g is a synthetic 39-amino-acid peptide investigated as a triple receptor agonist, interacting with three hormonal signalling receptors central to metabolism: the glp-1 receptor (glp-1r), the glucose-dependent insulinotropic polypeptide receptor (gipr), and the glucagon receptor (gcgr).

this simultaneous receptor activation distinguishes it mechanistically from classical glp-1 analogues. a lipophilic side-chain modification enhances albumin binding, prolonging systemic availability and reducing administration frequency.

phase 2 clinical data (nejm, 2023) documented dose-dependent reductions in body weight, visceral fat depots, and hepatic fat content. the triple activation mechanism is the subject of ongoing phase 3 investigation.

for research contexts only. references: jastreboff et al. nejm 2023 · sanyal et al. nature medicine 2024 · coskun et al. cell metabolism 2022. available upon request.

belle labs · re.triple-g

three receptors.
one decision.

access is by request only.

€449 per pen

request access →